Pfizer/Seagen: Deal Faces EC Probe with Bavencio Royalty Potentially at Issue

Published on Jun 29, 2023

Pfizer’s (PFE) plan to buy Seagen (SGEN) for $43 billion is said to face scrutiny by the European Commission following a referral request by the buyer. The deal could draw regulatory questions in Europe about a royalty payment Pfizer is set to receive for bladder cancer drug Bavencio, which appears to be an alternative to […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.